Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective boosted by Royal Bank of Canada from $160.00 to $170.00 in a research note issued to investors on Monday morning, The Fly reports.
JAZZ has been the subject of several other research reports. TheStreet raised Jazz Pharmaceuticals from a c+ rating to a b rating in a report on Thursday, August 20th. JPMorgan Chase & Co. assumed coverage on Jazz Pharmaceuticals in a report on Monday. They issued an overweight rating and a $175.00 price target for the company. Goldman Sachs Group cut Jazz Pharmaceuticals from a neutral rating to a sell rating and set a $128.00 price target for the company. in a report on Monday. Morgan Stanley raised Jazz Pharmaceuticals from an equal weight rating to an overweight rating and set a $177.00 price target for the company in a report on Thursday, August 6th. They noted that the move was a valuation call. Finally, SVB Leerink increased their price target on Jazz Pharmaceuticals from $160.00 to $169.00 and gave the company an outperform rating in a report on Monday, June 1st. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and sixteen have issued a buy rating to the stock. Jazz Pharmaceuticals currently has an average rating of Buy and an average target price of $161.81.
NASDAQ JAZZ opened at $144.13 on Monday. The company has a market cap of $7.99 billion, a PE ratio of 62.39, a price-to-earnings-growth ratio of 1.39 and a beta of 1.26. The stock’s 50 day simple moving average is $126.56 and its 200-day simple moving average is $113.84. Jazz Pharmaceuticals has a 1-year low of $86.88 and a 1-year high of $154.24. The company has a debt-to-equity ratio of 0.66, a current ratio of 5.62 and a quick ratio of 5.39.
In other news, CEO Bruce C. Cozadd sold 500 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $134.90, for a total transaction of $67,450.00. Following the completion of the transaction, the chief executive officer now directly owns 336,680 shares in the company, valued at $45,418,132. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last 90 days, insiders have sold 3,863 shares of company stock valued at $503,644. Company insiders own 4.60% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC grew its position in shares of Jazz Pharmaceuticals by 19.7% during the first quarter. AQR Capital Management LLC now owns 2,353,827 shares of the specialty pharmaceutical company’s stock worth $234,771,000 after buying an additional 387,575 shares in the last quarter. LSV Asset Management grew its holdings in Jazz Pharmaceuticals by 19.5% during the 2nd quarter. LSV Asset Management now owns 2,225,431 shares of the specialty pharmaceutical company’s stock worth $245,554,000 after acquiring an additional 363,015 shares in the last quarter. Thompson Siegel & Walmsley LLC acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth $36,250,000. Point72 Asset Management L.P. grew its holdings in Jazz Pharmaceuticals by 1,424.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 346,139 shares of the specialty pharmaceutical company’s stock worth $38,193,000 after acquiring an additional 323,439 shares in the last quarter. Finally, Sarissa Capital Management LP grew its holdings in Jazz Pharmaceuticals by 72.5% during the 1st quarter. Sarissa Capital Management LP now owns 765,000 shares of the specialty pharmaceutical company’s stock worth $76,301,000 after acquiring an additional 321,500 shares in the last quarter. 92.82% of the stock is currently owned by institutional investors.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: What is Liquidity?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.